Back to search

Article

<strong> </strong> Exploring the Therapeutic Potential of Hypericin: Molecular Docking with ABAD and BACE1 targets in Alzheimer's Disease Pathogenesis

2023-12-15

Abstract excerpt

This study employs molecular docking experiments to investigate the binding interactions of Hypericin with key proteins implicated in Alzheimer's disease (AD). Hypericin demonstrated a significant binding energy of -10.1 kcal/mol with ABAD (3-hydroxyacyl-CoA dehydrogenase type II). The analysis revealed multiple binding interactions, including hydrogen bonds with arginine 6, serine 7, and glutamic acid 140, as wel...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1ec5b7e9-7c58-512c-9176-f3f048c05882
DOI
10.20944/preprints202312.1188.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
<strong> </strong> Exploring the Therapeutic Potential of Hypericin: Molecular Docking with ABAD and BACE1 targets in Alzheimer's Disease PathogenesisDOI 10.20944/preprints202312.1188.v1
Network Pharmacology and molecular docking approach to unveil the mechanism of <i>Hypericum perforatum</i> in the management of Alzheimer’s disorderSemantic proximity
β-Secretase-1: In Silico Drug Reposition for Alzheimer’s DiseaseSemantic proximity
Machine Learning-Enhanced Drug Discovery for BACE1: A Novel Approach to Alzheimer's TherapeuticsSemantic proximity
Identification of dual inhibitors against BACE1 and GSK-3β for the treatment of Alzheimer’s disease: An in silico-based approachSemantic proximity
BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's diseaseSemantic proximity
Identification of new BACE1 inhibitors for treating Alzheimer’s diseaseSemantic proximity
Liver-X receptor β-selective agonist CE9A215 regulates Alzheimer’s disease- associated pathology in a 3xTg-AD mouse modelSemantic proximity
Synergistic Effect of Mutations in the Amyloidogenic Core of Human Amylin (hAM) Affords a New Potent Inhibitor of hAM Fibrillation: Computational Design and Experimental Validation.Semantic proximity
Evaluating Performance of Rigid and Flexible Docking Strategies for BACE1 Complexes: A Comparative Study of Physics-based and AI-Driven Docking MethodsSemantic proximity
Harnessing Escherichia coli’s Dark Genome to Produce Anti-Alzheimer PeptidesSemantic proximity
Synthesis, in vitro activity, and molecular docking of caffeic acid and resveratrol derivatives against Alzheimer's disease-related enzymesSemantic proximity
Identification Mechanism of BACE1 on Inhibitors Probed by Using Multiple Separate Molecular Dynamics Simulations and Comparative Calculations of Binding Free EnergiesSemantic proximity
Select a neighboring publication to make it the new centre.